Adams licensing agreement
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics will develop the mucoregulator compound erdosteine for prescription sale in the U.S. under a license and supply agreement with Italy's Edmond Pharma, the firms announce May 2. Erdosteine currently is marketed in Europe, South America and Asia for respiratory tract infections, bronchitis and chronic obstructive pulmonary disease. Adams expects to conduct Phase II trials pending the filing of an investigational new drug application with the FDA expected "later this year." The mucus-thinning compound complements the company's respiratory portfolio, which includes the OTC extended-release guaifenesin product Mucinex...